Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies

[1]  W. J. Ramsey,et al.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine , 2017, The New England journal of medicine.

[2]  Lauren A. Cowley,et al.  Unique human immune signature of Ebola virus disease in Guinea , 2016, Nature.

[3]  S. Khurana,et al.  Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins , 2016, PLoS pathogens.

[4]  Louis B. Justement,et al.  Faculty Opinions recommendation of Class-switched memory B cells remodel BCRs within secondary germinal centers. , 2016 .

[5]  James E. Crowe,et al.  Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection , 2016, Cell.

[6]  James D. Campbell,et al.  Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial , 2016, The Lancet. Infectious diseases.

[7]  Edward Wright,et al.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.

[8]  Jonathan R. Lai,et al.  Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses , 2015, Journal of Virology.

[9]  Jon Cohen,et al.  CLINICAL TRIALS. Ebola vaccines face daunting path to approval. , 2015, Science.

[10]  H. Feldmann,et al.  Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus , 2015, The Journal of infectious diseases.

[11]  P. Krause.  Interim results from a phase 3 Ebola vaccine study in Guinea , 2015, The Lancet.

[12]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial , 2015, The Lancet.

[13]  J. Rucker,et al.  Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies , 2015, Journal of Virology.

[14]  J. Strong,et al.  VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain , 2015, Science.

[15]  M. Nussenzweig,et al.  T cell help controls the speed of the cell cycle in germinal center B cells , 2015, Science.

[16]  G. Glenn,et al.  ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. , 2015, Vaccine.

[17]  Andrea A. Berry,et al.  Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. , 2015, JAMA.

[18]  M. Cavaleri,et al.  Approaches to demonstration of Ebola virus vaccine efficacy. , 2015, The Lancet. Infectious diseases.

[19]  Steven F. Baker,et al.  High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. , 2015, The Journal of infectious diseases.

[20]  H. Feldmann,et al.  Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses , 2015, Emerging infectious diseases.

[21]  P. Milpied,et al.  Switched-memory B cells remodel B cell receptors within secondary germinal centers , 2015, Nature Immunology.

[22]  Christopher Dye,et al.  Ebola vaccine--an urgent international priority. , 2014, The New England journal of medicine.

[23]  X. Qiu,et al.  Structures of protective antibodies reveal sites of vulnerability on Ebola virus , 2014, Proceedings of the National Academy of Sciences.

[24]  D. Bernstein,et al.  Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. , 2014, JAMA.

[25]  Larry M. Baddour,et al.  Ebola Virus Disease in Guinea , 2014 .

[26]  R. Karron,et al.  A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. , 2014, The Journal of infectious diseases.

[27]  Yang Zhang,et al.  The I-TASSER Suite: protein structure and function prediction , 2014, Nature Methods.

[28]  B. Graham,et al.  DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. , 2013, The Journal of infectious diseases.

[29]  J. Mascola,et al.  Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. , 2013, The Journal of infectious diseases.

[30]  H. Feldmann,et al.  Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine , 2013, PLoS pathogens.

[31]  M. Katze,et al.  Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.

[32]  X. Qiu,et al.  Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates , 2012, Science Translational Medicine.

[33]  Majidat A. Muhammad,et al.  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease , 2012, Proceedings of the National Academy of Sciences.

[34]  J. Yewdell,et al.  MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.

[35]  R. Rappuoli,et al.  Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus , 2010, Science Translational Medicine.

[36]  Heinz Feldmann,et al.  Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus , 2009, Journal of Virology.

[37]  K. Subbarao,et al.  Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets , 2009, PLoS medicine.

[38]  D. Burton,et al.  Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor , 2008, Nature.

[39]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[40]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[41]  J. Wilson,et al.  Epitopes involved in antibody-mediated protection from Ebola virus. , 2000, Science.